Brand: Geneith

Camosunate Junior is a fixed-dose Artemisinin-based Combination Therapy (ACT) antimalarial specifically formulated for children between the ages of 7 and 13. It contains a combination of Artesunate (100mg) and Amodiaquine (300mg). It is primarily used for the treatment of acute, uncomplicated malaria, including strains that may be resistant to older drugs like chloroquine.